Since RhoC is one of the few antigens which has been shown to be expressed in metastatic disease, we propose that targeting this protein by vaccination should be combined, e.g., with checkpoint inhibitor therapy, to increase clinical efficacy. This evidence concerns the gene RHOC and metastatic neoplasm.